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Background
Previous analysis of primary prostate cancer (PCa), its metastasis to lymph nodes and circulating tumor cells (CTCs) revealed that loss of the prominent tumor suppressor gene BRCA1 can be one signature of PCa aggressiveness and its dissemination to regional lymph nodes and peripheral blood [1] . BRCA1 function-offmutations are well described in development and progression of different solid tumors particularly breast and ovarian cancers but also PCa. Germline BRCA1 mutations are shown to be associated with the higher risk of the onset of PCa and/or more aggressive course of the disease [2] [3] [4] . Of note, BRCA1 dysfunction might be particularly interesting in the context of poly(ADP-ribose) polymerases (PARP)
inhibitor-based therapies, tested currently in some clinical trials including also patients with PCa in such trials as TOPARP trial (NCT01682772), PROFound study (NCT02987543) and TRITON3 (NCT02975934) [5] . The identified gains of BRCA1 seemed to be irrelevant for the PCa patients' outcome but it might have been biased by the low number of cases with such characteristics [1] .
The molecular associations of BRCA1 gene loss in PCa remain unclear. BRCA1 is known to be a pivotal regulator of a plethora of cellular processes, which, when defected, might be involved in tumor progression [6] . It includes cell cycle control, DNA repair, transcription and ubiquitination [7] [8] . BRCA1-mutated or -deficient breast cancer cells seem to have more invasive phenotype including higher proliferation rate [9[ and migration abilities [10] [11] [12] . Moreover, in breast cancer in vitro and mouse models it was also shown that BRCA1 alterations could result in epithelialmesenchymal transition (EMT) [10, 13, 14] and even influence cellular fate by inducing expression of proteins involved in stemness programme [15, 16] . Of note, in peripheral blood of metastatic PCa patients, it seemed that mesenchymal cell marker vimentin identified cells with BRCA1 loss more frequently than common cytokeratin (CK) staining [1] , which might suggest that such a phenomenon takes place also in PCa.
In the current work, the clinical associations of BRCA1 gene aberrations found in the previous studies [1, 17] were evaluated on the large cohort of patients. Additionally, to investigate potential phenotype of BRCA1-gene-deficient PCa, expression of selected proteins in PCa was determined in relation to the status of BRCA1 gene.
The set of the analysed proteins included proliferation (Ki-67) and apoptosis markers (ApopTags), basal (CK 5/6, CK14) and luminal cytokeratins (CK8/18 and CK19), mesenchymal marker vimentin, two cadherins (E-and N-cadherin) which changes are known to be associated with EMT induction, stem cell marker (ALDH1) as well as potent regulator of cellular growth, stemness, and EMT (EGFR).
Methods

Patients
One thousand one hundred ninety nine patients who underwent radical prostatectomy at the Department of Urology University Hospital Münster (Germany) and overall survival (OS) data were collected. Biochemical recurrence was defined as two consecutive concentrations of prostate specific antigen (PSA) above 0.1 ng/mL
The time point of recurrence was defined as the first PSA concentration above 0.1 ng/mL The last follow-up was performed in October 2014. In average, the patients were observed for 60 months. The maximum observation period lasted 223 months (approx. 18 years). Information about patients' death and occurrence of overt metastasis was documented. The study was conducted according to REMARK study recommendations [18] .
Clinical material
Clinical material was prepared as six tissue microarrays (TMAs) as described [1] .
Briefly, 4-μm-thick sections of TMAs comprised of 398 tissue cores (diameter of 0.6 mm) corresponding to 199 patients each were prepared for both fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC). The patients with multifocal PCa were represented on TMA by tissue cores obtained from two different tumor foci.
Normal prostate tissues were included in TMAs and evaluated as internal controls.
Fluorescent In Situ Hybridization for assessment of BRCA1 gene dosage
Fluorescent in situ hybridization (FISH) protocol was applied as described [1] . Based on the previously assessed clinical impact of BRCA1 gene [1] , the cut-off to categorize BRCA1 gene dosage was defined as ≤0.75 for BRCA1 losses, 0.75-1.25 for normal gene dosage and ≥1.25 for gains. Matching lymph node metastases were evaluated for BRCA1 gene dosage before [1] .
Immunohistochemistry for BRCA1 and selected proteins BRCA1 protein expression was performed as described (19) . Briefly, deparaffinised specimens were incubated after antigen retrieval (citrate buffer, pH 6.0, 20 min. at Immunohistochemistry for CK5/6, CK14, CK8-18, CK19, E-cadherin, N-cadherin, vimentin, apoptotic marker, Ki-67, ALDH1 and EGFR were performed as described 
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Statistics
Statistical analysis was performed with the usage of SPSS software version 24.0 licensed for University of Gdańsk. Chi-square or Fisher's exact tests were used in order to compare the results to molecular factors or clinico-pathological parameters.
Associations between BRCA1 gene status and time to biochemical recurrence or to metastasis were evaluated using Log Rank (Mantel Cox) test and Kaplan-Meier plot.
To estimate hazard risk, Cox-Hazard-Potential regression analysis (CI 95%) was done. All results were considered statistically significant if p<0.05 and highly statistically significant if p<0.001. Cases with missing data were excluded from analysis. No mutations were found in these patients (data not shown). Additionally, no BRCA1 promoter methylation was found in these patients as described [1] . When BRCA1 gene dosage and protein expression were compared in subpopulation of PCa (n=203), 4 out of 10 (40%) tumors with BRCA1 gene gain were characterized by loss of nuclear BRCA1 protein expression or its localisation in cytoplasm (Suppl. Table   2 ).
Results
Frequency of BRCA1 gene aberrations in primary prostate cancer
Intratumoral heterogeneity of PCa in regard to BRCA1 aberrations
Two-hundred-thirty-four patients were informative for BRCA1 gene dosage in two tissue samples originated from two separated tumor foci. Both gene losses and gains were found predominantly in exclusively one tumor focus. In total, differences in In the total cohort of patients, BRCA1 gene gains predicted shorter time to metastasis (Chi 2 =6.312, p=0.012) (Fig. 1A) . In the patients characterized by Gleason score >7, BRCA1 losses correlated with shorter time to biochemical recurrence (Chi 2 =5.280, p=0.022; median time to biochemical recurrence 27 vs. 113 months for patients with BRCA1 gene loss or normal gene dosage, respectively) (Fig. 1B) . In this subgroup of patients, BRCA1 gene losses appeared also to be an independent prognostic marker of shorter time to biochemical recurrence (Cox analysis, p=0.005, CI95% 0.336, HR 0.158-0.715) (Tab. 2).
Associations of BRCA1 gene aberrations with cancer phenotypes
Primary tumors with BRCA1 gene losses and gains displayed significantly more frequently stem cell marker ALDH1 (Fisher exact test, p=0.021 and p=0.014, respectively) (Tab. 3). However, there was no correlation of BRCA1 gene status to 
Discussion
In our previous report on PCa, BRCA1 gene losses were found to correlate with more advanced stage of the disease, dissemination of tumor cells and worse clinical outcome [1] . The present study was designed in order to validate these findings in a large cohort of patients. Furthermore, this study aimed to determine tumor molecular features associated with the aberrations of BRCA1 gene and potentially involved in PCa progression such as proliferation, epithelial-mesenchymal transition or stem-celllike phenotype.
The distribution of BRCA1 gene aberrations was similar to the previously reported: BRCA1 gene losses appeared in 10% and gains in 7% of the analyzed patients [1] .
The intratumoral heterogeneity was defined in almost one seventh of the tumors analyzed in two tumor samples, which confirms the molecular multiplicity of prostate cancer. Common molecular alterations of BRCA1 gene such as hypermethylation of the promoter and/or known germline base (ex)change mutations did not account for BRCA1 gene loss-of-function in tumors with BRCA1 gene gain. However, other chromosomal aberrations might be the causative that did not disrupt FISH probe binding but e.g. interactions with one of the multiple binding proteins of BRCA1 [20, 21] . Of note, 40% of the investigated tumors with BRCA1 gene gain were characterized by cytoplasmic BRCA1 protein expression or loss of nuclear BRCA1 expression. BRCA1 absence in nuclei and/or mislocalisation in cytoplasm might result in dysfunction of BRCA1 as tumor suppressor e.g. by affecting its role in DNA damage repair [21, 22] . Therefore, it might be assumed that at least a part of those tumors do not have fully functional BRCA1 protein, which merits further investigation.
The current study corroborated the associations of BRCA1 gene losses to more advanced tumor disease defined by higher T status and Gleason score in the large cohort of patients. BRCA1 gene losses indicated also shorter time to biochemical recurrence in the patients characterized by Gleason score >7. Of note, BRCA1 gene losses occurred to be an independent prognostic marker in this group of patients, which hypothetically might facilitate the treatment decisions in this high risk group of patients in the future. It is conceivable that such patients might profit from poly(ADPribose)polymerase (PARP) inhibitors already tested in some clinical trials or other sort of therapeutics expected to function in BRCA1-deficient tumors [22] .
In addition, beside gene losses BRCA1 gene gains were detected, which also correlated to shorter time to metastasis. Thirty-six percent of patients analyzed for matched tumor -LNM samples had BRCA1 gene losses in LNMs. Our previous results [1, 17] and study on PCa metastases using next generation sequencing [4] suggest that not only germline mutations but also somatic BRCA1 gene losses might be associated with tumor dissemination to distant organs. In the current study, BRCA1 gene losses could have been tracked in both primary and secondary tumor site only in 2 patients. However, BRCA1 gene losses might be present only in one even smaller tumor focus [1, 17] or in a small subpopulation of tumor cells as we have already shown by analysing whole sections of tumors [1] . It might be reasoned that patients with BRCA1 gene loss found exclusively in LNM might still carry BRCA1 gene losses in another focus of the primary tumor which had been missed during evaluation of small tumor fragments such as TMA tissue cores.
BRCA1 plays different roles including control of cell cycle [6] and speculated regulation of differentiation of breast (cancer) stem cells [23] [24] [25] . Herein, we cannot define a clear phenotype of PCa with BRCA1 gene losses or gains. Both tumors with BRCA1 gene losses and BRCA1 gene gains displayed more frequently ALDH1 known to characterize stem cells in different types of organs [26] . BRCA1 gene losses were also associated to the expression of EGFR, a regulator of plethora of different cellular processes including growth, stemness and EMT [27] . Based on these associations, it might be assumed that BRCA1 gene aberrations occur in the subpopulation of PCa stem cells or induce stem cell programme (dedifferentiation process) in PCa cells.
Conclusions
In conclusion, in the current large study it was substantiated that BRCA1 gene losses 
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